Puma Biotechnology (PBYI) has a PEG ratio of 45.99, above the Healthcare sector average of 0.46.
Get informed when a big investor buys or sells
+ Follow45.99
The PEG ratio measures a stock's valuation relative to its earnings growth rate. A PEG ratio below 1.0 may indicate that the stock is undervalued relative to its growth potential.
Puma Biotechnology posts a PEG ratio of 45.99. That is above the Healthcare sector average of 0.46. Comparing that reading with peers and prior periods is usually more useful than looking at the number in isolation.
For Healthcare stocks, a PEG ratio near 0.46 is typical. Puma Biotechnology's 45.99 is higher that level. That is roughly 9820.7% above the sector mean. Whether that is a warning or an opportunity depends on growth outlook and other fundamentals shown elsewhere on Stockcircle.
Puma Biotechnology's PEG ratio of 45.99 comes from dividing a price-based measure by a related financial statistic. Changes can come from the stock price moving, the underlying fundamental shifting, or both. Track both the level and the trend — a rising multiple on falling fundamentals is a different story than a rising multiple on rising earnings.
Context for PBYI's PEG ratio usually means three checks: (1) trend versus prior periods, (2) level versus peers (average 0.46), and (3) consistency with growth and profitability. This page covers the first two; Puma Biotechnology's other metric pages and overview cover the third.
Judging Puma Biotechnology against Healthcare peers is usually better than using a market-wide rule of thumb. Business models inside Healthcare are more comparable, which makes gaps in PEG ratio easier to interpret. Start with 45.99 here, then scan peer and history charts to see if the gap is persistent.